| Issuer | % of Class | Filed |
|---|---|---|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 9
ASBP · 738920305
|
7.9% |
8/6/2026
Event 8/4/2026
|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 9
ASBP · 738920107
|
4.5% |
5/19/2025
Event 5/6/2025
|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 8
ASBP · 738920107
|
7.9% |
5/7/2025
Event 4/29/2025
|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 7
ASBP · 738920107
|
8.3% |
4/23/2025
Event 4/21/2025
|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 6
ASBP · 738920107
|
8.3% |
4/17/2025
Event 4/11/2025
|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 5
ASBP · 738920107
|
8.6% |
4/11/2025
Event 4/4/2025
|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 4
ASBP · 738920107
|
9.0% |
4/4/2025
Event 3/26/2025
|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 3
ASBP · 738920107
|
9.1% |
3/28/2025
Event 3/19/2025
|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 2
ASBP · 738920107
|
9.5% |
3/20/2025
Event 3/3/2025
|
|
Aspire Biopharma Holdings, Inc.
13G/A
Amendment 1
ASBP · 738920107
|
9.8% |
3/12/2025
Event 3/3/2025
|
|
Aspire Biopharma Holdings, Inc.
13G
ASBP · 738920107
|
10.0%
Checked 5% or less
|
2/26/2025
Event 2/17/2025
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.